AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales

Fears that Humira biosimilars will erode AbbVie's topline are overblown, an analyst said Monday. He has an outperform rating on AbbVie stock. The post AbbVie Outlook: Why Humira Biosimilars Won't Undo Huge Sales appeared first on Investor's Business Daily....